Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this Phase I open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with tremor as a results of Parkinson's Disease or Essential Tremor.
This study is designed to evaluate the safety and efficacy of focused ultrasound in patients with Parkinson's Disease or Essential Tremor characterized by tremor. The safety of this protocol will be closely monitored and data will be used to determine whether any significant safety issues exist when using focused ultrasound. Adverse events will be noted whenever they occur but will be recorded at the time of the procedure and throughout routine follow-ups, which will persist weekly throughout the duration of the active study protocol. Patients deemed potentially appropriate candidates for focused ultrasound therapy will be treated with 8 sessions of transcranial ultrasound, each of which consists of 10 to 30 minutes of active administration. Clinical and safety outcome measures will be obtained throughout and after completion of the study protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental | Experimental | Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Focused Ultrasound | Device | The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement. |
| Measure | Description | Time Frame |
|---|---|---|
| Essential Tremor Rating Assessment Scale (TETRAS) | The Essential Tremor Rating Assessment Scale was developed by the Tremor Research Group to quantify essential tremor severity and its impact on activities of daily living. The ADL section of TETRAS has 12 items, each rated 0, 1, 2, 3 or 4. The maximum total score is 48. Item 1 addresses speech; item 10 addresses occupational impairment; and item 12 assesses social impact. The other 9 items assess activities that are affected primarily by upperweighting of lower limb tremor in the total performance score. | Baseline |
| Essential Tremor Rating Assessment Scale (TETRAS) | The Essential Tremor Rating Assessment Scale was developed by the Tremor Research Group to quantify essential tremor severity and its impact on activities of daily living. The ADL section of TETRAS has 12 items, each rated 0, 1, 2, 3 or 4. The maximum total score is 48. Item 1 addresses speech; item 10 addresses occupational impairment; and item 12 assesses social impact. The other 9 items assess activities that are affected primarily by upperweighting of lower limb tremor in the total performance score. | Through Completion of Study (Average time 8-weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| 9 Hole Pegboard Task (9 HPT) | A validated assessment for fine motor skills, the 9-HPT involves having a participant move 9 pegs individually from starting position to 9 separate peg-holes, as quickly as possible, and to immediately return the 9 pegs to the starting position upon filling the final peg-hole. This is performed separately for each hand. The score is the time (seconds/milliseconds) that it takes to complete the task, recorded separately for dominant and non-dominant hands. The minimum detectable change is 2.6 seconds for the dominant hand and 1.3 seconds for the non-dominant hand. |
Not provided
Inclusion Criteria:
In order for a subject to be considered for the Essential Tremor application of this study, the following criteria are required:
Subjective complaint of tremor assessed and validated by physician
Must be willing to comply with the study protocol
English Proficiency
At least 18 years of age
At most 90 years of age
In order for a subject to be considered for the Parkinson's Disease application of this study, the following criteria are required:
Diagnosis of Parkinson's Disease validated by physician
Must be willing to comply with the study protocol
English Proficiency
At least 18 years of age
At most 90 years of age
Exclusion Criteria:
In order for a subject to be considered for this study, he/she may NOT have any of the following:
Subjects not English proficient
Subjects unable to give informed consent
Subjects do not meet age requirements (18-90)
Subjects who would not be able to lay down without excessive movement in a calm environment sufficiently long enough to be able to achieve sleep
Pregnancy, women who may become pregnant or are breastfeeding
Women with child-bearing potential who are not willing to use a double-barrier birth control method
Males not willing to use a double-barrier birth control method with female sex partners with child-bearing potential
Advanced terminal illness
Any active cancer or chemotherapy
Any other neoplastic illness or illness characterized by neovascularity
Macular degeneration
Subjects with scalp rash or open wounds on the scalp (for example from treatment of squamous cell cancer)
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rama Surya | Contact | 3108295968 | 214 | jsurya@theneuroassociates.com |
| Jon Haroon | Contact | 3108295968 | 214 | jharoon@theneuroassociates.com |
| Name | Affiliation | Role |
|---|---|---|
| Sheldon Jordan, MD | The Regenesis Project | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Neurological Associates of West Los Angeles | Recruiting | Los Angeles | California | 90403 | United States |
Not provided
| ID | Term |
|---|---|
| D014202 | Tremor |
| D010300 | Parkinson Disease |
| D020329 | Essential Tremor |
| ID | Term |
|---|---|
| D020820 | Dyskinesias |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline |
| 9 Hole Pegboard Task (9 HPT) | A validated assessment for fine motor skills, the 9-HPT involves having a participant move 9 pegs individually from starting position to 9 separate peg-holes, as quickly as possible, and to immediately return the 9 pegs to the starting position upon filling the final peg-hole. This is performed separately for each hand. The score is the time (seconds/milliseconds) that it takes to complete the task, recorded separately for dominant and non-dominant hands. The minimum detectable change is 2.6 seconds for the dominant hand and 1.3 seconds for the non-dominant hand. | Through Completion of Study (Average time 8-weeks) |
| Parkinson's Activities of Daily Living Scale (PAD-L) | The Parkinson's Activities of Daily Living Scale is a self-report activities of daily living scale designed to assess difficulties in daily activities due to symptoms of Parkinson's Disease. | Baseline |
| Parkinson's Activities of Daily Living Scale (PAD-L) | The Parkinson's Activities of Daily Living Scale is a self-report activities of daily living scale designed to assess difficulties in daily activities due to symptoms of Parkinson's Disease. | Through Completion of Study (Average time 8-weeks) |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |